Smarter evidence, faster decisions: How AI is transforming clinical development and commercialization

Generating high-impact real-world evidence is resource-intensive. However, it is critical to accelerate development, strengthen regulatory and payer positioning, secure favorable market access and differentiate your product in a competitive landscape.

AI is redefining how evidence is generated, operationalized and scaled.

In this discussion, you’ll learn about:

• Proactive analytics that identify clinical trial enrollment and site performance risks early.
• AI-driven data feasibility and optimal dataset selection.
• Machine learning and natural language processing (NLP) that convert fragmented real-world data into analysis-ready datasets.
• Extraction of clinically meaningful insights from unstructured clinical notes and patient interactions.
• AI-enabled economic modeling and payer strategy optimization.

Access the full discussion to discover how Thermo Fisher Scientific is helping leading organizations deploy AI, integrated with scientific and clinical expertise, to reduce development risk, compress timelines, and transform real-world data into strategic evidence that drives confident decision-making.